$1.16
▲ +$0.01
(+0.87%)
Vol 801K
1
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$64.2M
ROE
-370.4%
D/E
0.00
Beta
1.56
52W
$1–$1
Wall Street Consensus
15 analysts · Apr 20266
Strong Buy
8
Buy
1
Hold
0
Sell
0
Strong Sell
93.3%
Buy Rating
Price Chart
Similar Stocks
WHWK
Whitehawk Therapeutics Inc
$114.1M
NKTX
Nkarta Inc
$131.4M
ABOS
Acumen Pharmaceuticals Inc
$127.8M
VTVT
vTv Therapeutics Inc
$167.1M
KALA
KALA BIO Inc
$12.2M
TNYA
Tenaya Therapeutics Inc
$154.0M
HRTX
Heron Therapeutics Inc
$238.4M
UNCY
Unicycive Therapeutics Inc
$124.0M
DTIL
Precision BioSciences Inc
$100.1M
Earnings
Beat rate: 50.0%
Next Report
May 13, 2026
EPS Estimate: $-0.09
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.09 | — | — |
| Dec 2025 | $-0.10 | $-0.07 | +$0.03 |
| Sep 2025 | $-0.17 | $-0.13 | +$0.04 |
| Jun 2025 | $-0.17 | $-0.20 | $-0.03 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net Income | — | -$25.2M | -$25.5M | -$26.8M | -$25.6M | -$19.3M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -244.9% | -244.9% | -244.9% | -244.9% | -370.4% | -370.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 2.19 | 2.19 | 2.19 | 2.19 | 1.31 | 1.31 |
Key Ratios
ROA (TTM)
-252.1%
P/B
4.9
EPS (TTM)
$-0.84
CF/Share
$-3.00
52W High
$1.39
52W Low
$0.54
$0.54
52-Week Range
$1.39
Financial Health
Free Cash Flow
-$19.3M
Net Debt
-$14.9M
Cash
$15.5M
Total Debt
$577K
As of Dec 31, 2025
How does IMUX compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
IMUX valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
4.9
▲
99%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
IMUX profitability vs Biotechnology peers
ROE
-370.4%
▼
450%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-252.1%
▼
440%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
IMUX financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
1.3
▼
71%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
1.6
▲
60%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
IMUX fundamentals radar
IMUX
Peer median
Industry
IMUX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
IMUX vs peers: key metrics
Top Holders
Top 5: 23.0%Aberdeen Group plc
6.32%
$9.3M
BVF Inc.
5.87%
$8.6M
Vanguard Group Inc
3.85%
$5.7M
Avidity Partners Management…
3.60%
$5.3M
Nantahala Capital Managemen…
3.36%
$4.9M
As of Dec 31, 2025